SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Immunomedics (IMMU) - moderated
An SI Board Since September 2006
Posts SubjectMarks Bans Symbol
63361 356 15 IMMU
Emcee:  idahoranch1 Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
62718Sorry, I don't know Nachtrab. I was just wondering if by CASA expanding theweatherproof17/31/2024
62717I like the way you re-positioned the question. Do you think if the unblinded datjhcimmu-7/31/2024
62716Allow me to ask the question in a different manner. With no FDA guidance or somweatherproof-7/31/2024
62715My understanding is not that SAVA is drawing a target around a landed arrow, butjhcimmu-7/31/2024
62714Thanks for taking the time to regurgitate the statistical perspective. Forgive weatherproof17/31/2024
62713[graphic]ghettogoulash17/31/2024
62712IMNN: Phase 2 data for ovarian cancer is crazy good. Specifically, Overall Survighettogoulash-7/31/2024
62711And it's down big time, LOL. I guess results were not significant. I thinkkdd99917/31/2024
62710simufilam OL time zero data tells the whole story...been mentioned here before, scorman147/31/2024
62709From ClinicalTrials.gov on CASA's OL trial (the boldface and underline is frweatherproof17/30/2024
62708I did pick up a few shares of CASA a couple weeks ago at $9.81, but wishing I boweatherproof27/30/2024
62707Cassava Sciences Announces Expansion of Open-Label Extension Trials Of course, erickerickson47/30/2024
62706Cognition Therapeutics announces positive results from trial of oral treatment ferippetoe-7/29/2024
62705Sysiphus - Here are my thoughts on that article: The headline includes the use weatherproof17/29/2024
62704finance.yahoo.comsysiphus-7/29/2024
62703Results from AVXL ph 2b/3 AD trial: anavex.comweatherproof27/29/2024
62702Stew, my read is that they're going for AA and part of that equation is to aweatherproof17/26/2024
62701from Aug 2023 conf call With newly available preliminary efficacy results of sscorman117/26/2024
62700>>Biogen Inc. TOKYO and CAMBRIDGE, Mass., July 26, 2024 (GLOBE NEWSWIRE) -weatherproof17/26/2024
62699>> the company has clearly stated that a new FDA phase 3 is required, sweatherproof27/26/2024
62698on AVXL: When EF Hutton speaks.....they should get their facts straight in the fscorman147/25/2024
62697investing.comsysiphus17/25/2024
62696AVXL has already announced they will need a full phase 3, 1 1/2yr trial for AD, scorman117/25/2024
62695FWIW - AVXL was $3.70 in June and broke $7 earlier today. It's catching up weatherproof27/25/2024
62694Simufilam treatments will be extended to patients who have completed extension tscorman157/24/2024
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News